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Abstract
Advances in molecular techniques have shown that genetic factors predispose individu‐
als to cardiovascular diseases (CVD). These techniques have made it possible to iden‐
tify disease‐causing genes, prediction to disease susceptibility and responsiveness to 
drug interventions. For the purpose of this review, therapeutic intervention (niacin) was 
conducted in a nonhuman primate model to assess the impact of six coincident single 
nucleotide polymorphisms (cSNP) identified in prioritised reverse cholesterol transport 
(RCT) and high‐density lipoprotein (HDL) metabolism genes. Gene expression findings 
confirmed that these genetic variants may have a direct impact on the RCT pathway and 
drug intervention (niacin) response.
Keywords: cardiovascular disease (CDV), candidate genes, HDL‐C metabolism, 
sequence variants, reverse cholesterol transport (RCT)
1. Introduction
Cardiac and vascular complications are complex multifactorial pathologies and difficult to 
prevent since are associated with both genetic and environmental factors [1]. Research on car‐
diovascular diseases (CVDs) is constantly evolving and the current focus is directed towards 
lipid metabolism, molecular and cellular mechanisms, as well as preventive strategies. Most 
research in the field of lipid metabolism is motivated by an interest to understand normal lipid 
transport and preventative measures for atherosclerosis abnormalities [2]. Specific genes and 
apolipoproteins that are involved in lipid metabolism and lipoprotein synthesis have been 
isolated, sequenced and mapped in the human genome [3]; however, their role in the lipid 
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metabolism and lipid transport can only be inferred by physiological and genetic  studies. To 
determine their overall function, further exploration of genetic alterations must be investigated.
Since the molecular regulation of lipid metabolism and reverse cholesterol transport (RCT) 
pathway is complex, numerous studies in humans, animals and in vitro have been focusing 
on the protective action of high‐density lipoprotein cholesterol (HDL‐C), RCT and cholesterol 
efflux, which can also be augmented for potential therapeutic strategies of CVDs [4, 5].
2. Overview of RCT and cholesterol efflux
The RCT pathway represents an important process involving the transfer of excess cholesterol 
by HDL particles to the liver for excretion. The ability of HDL to remove cholesterol from cells 
such as macrophages is linked to the anti‐inflammatory and immunosuppressive functions of 
this lipoprotein [6]. However, the functionality of HDL is impaired in humans with chronic 
inflammatory diseases and this causes a reduction in the anti‐inflammatory and cholesterol 
transport properties. Studies have shown that apolipoprotein A‐I (ApoA‐1), lecithin‐choles‐
terol acyltransferase (LCAT), ATP‐binding cassette transporter A1 (ABCA1) and scavenger 
receptor class B type 1 (SR‐B1) serve as important cofactors for a number of RCT pathway con‐
stituents [7]. The initial step of the pathway involves ApoA‐1 being produced by the liver and 
released into the plasma where it is involved in all stages, including the formation of nascent 
HDL particles, HDL remodelling by LCAT and delivery of HDL cholesterol directly to the 
liver via SR‐BI or indirectly via CETP‐mediated transfer to apoB‐containing lipoproteins [8]. 
Through this process, cholesterol efflux is promoted from the macrophages via ABCA1 and 
also by the ABCG1 transporter using the action of LCAT (Figure 1).
Figure 1. Reverse cholesterol transport (RCT) pathway. Major components of RCT include apolipoprotein A‐I (apoA‐I), 
high‐density lipoprotein (HDL), lecithin: cholesterol acyltransferase (LCAT), ATP‐binding cassette transporter (ABCA1/
ABCG1) and cholesterol ester transfer protein (CETP). Free cholesterols (FC) in the HDL are delivered to the liver for 
excretion through scavenger receptor B1 (SR‐B1). Alternatively, the cholesteryl esters (CE) could also be delivered to the 
liver through the low‐density‐lipoprotein receptor (LDLR). Figure modified from Rader et al. [4].
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3. Vervet monkey as an animal model for CVDs
As with most areas of human biology, studies of human CVDs have been enriched and com‐
plemented by investigations of animal models. Among the nonhuman primates (NHP), the 
vervet monkey (Chlorocebus aethiops) has been validated to be an excellent research model for 
the study of CVDs [9]. For the purpose of this investigation, we used this NHP model to deter‐
mine the protective action of HDL, its role in the reverse cholesterol transport (RCT) pathway 
and the expression profile of genes regulating HDL metabolism.
This study was conducted in compliance with the Public Health Service (PHS) Policy on 
Humane Care and Use of Laboratory Animals (A5726‐01) and approved by the Ethics 
Committee of the South African Medical Research Council (SAMRC) (REF 11/07). The 
selected subjects (25) were healthy adult female monkeys with normal plasma HDL. All 
individuals were kept under identical housing conditions according to the South African 
National Standard for the Care and Use of Animals for Scientific Purposes (The SANS 
10386:2008).
3.1. Laboratory analysis
3.1.1. Candidate genes and sequence variants selection
The genetic variations were evaluated in 10 genes implicated in lipid metabolism (CETP, 
ABCA1, CYP7A1, apoA‐1, apoB, apoE, SR‐B1, LCAT, apoCI and apoCII). Twenty‐two coin‐
cident single nucleotide polymorphisms (cSNPs) were selected for genotyping. These cSNPs 
were prioritised based on their function and location within their respective candidate gene 
and their association with CVD.
3.1.2. Gene expression
Blood (2 ml) was collected in EDTA‐containing tubes from 25 animals using a femoral vene‐
puncture after ketamine anaesthesia at 10 mg/kg bodyweight. DNA was extracted from 
whole blood using the Nucleospin Genomic Blood DNA Purification Kit (MACHEREY‐
NAGEL, Germany) and PAXgene Blood RNA Kit (PreAnalytiX, Qiagen) was used for 
RNA extraction. The extracted DNA was used for Sanger sequencing while RNA was 
for gene expression experiments. Turbo DNase treatment (Ambion, USA) was used for 
RNA purification before cDNA conversion (high‐capacity cDNA kit, Applied Biosystems, 
USA). The effects of niacin treatment on the expression of the 10 prioritised genes were 
determined using quantitative real‐time PCR (qRT‐PCR). The gene expression data were 
normalised to the average of phosphoglycerate kinase 2 (PGK2: QT00219023) and glycer‐
aldehyde‐3‐phosphate dehydrogenase (GAPDH: QT01192646), which were used as house‐
keeping genes.
Since the levels of high‐density lipoprotein‐cholesterol (HDL‐C) are a significant determi‐
nant of a cholesterol efflux capacity, a correlation analysis was conducted to determine the 
relationship between the levels of HDL‐C and mRNA expression of the 10 selected RCT can‐
didate genes.
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4. Effects of mutations, drug intervention and gene expression on RCT
A major area in HDL‐based therapeutics is focusing on the development of pharmacological 
approaches to improve the activity of the RCT pathway. One of these strategies involves the 
combination of genetic variations and individual responsiveness to drugs [10]. Subsequently, 
genetic variations in gene encoding transporters contribute to individual differences in drug 
absorption, elimination and cellular uptake, thereby affecting drug response and toxicity [11].
Among several types of genetic variations, single‐nucleotide polymorphisms (SNPs) are the 
most abundant throughout the genome [12]. SNPs have lately received much attention as they 
serve as markers of individual risk for adverse drug reactions or susceptibility to complex 
diseases [13]. Small‐scale studies have focused on the effects of polymorphisms on physi‐
ological or biochemical factors and have provided useful information on possible mechanistic 
links between variation at the gene level and risk factors for CVDs [14]. For the purpose of 
this review, 10 ‘candidate’ genes known to be involved in RCT and HDL metabolism were 
screened in the vervet model and only six cSNPs (I405V, I883M, A233S, cL96R, ‐62A>C and 
A350A) were identified in CETP, ABCA1, CYP7A1, apoCII and SR‐B1, respectively (Table 1).
For effective changes in lipid metabolism, niacin, as the most potent available lipid‐regulat‐
ing drug [7] was used as a tool to increase HDL levels (Figure 2). A strong inverse correlation 
was observed with CETP, SR‐B1 and CYP7A1 concentrations (r = ‐0.14, ‐0.27, ‐0.30; p < 0.001). 
Concurrently, gene expression profile showed that all three genes were down‐regulated when 
correlated with the three cSNPs (I405V, A350A and A233S) (Figure 3). Since I405V is known 
to lower plasma CETP concentration and elevate HDL‐C concentration [5, 9], the presence of 
this variant confirmed the same effect in the vervet model. With a similar expression profile 
observed in SR‐B1 and CYP7A1, the presence of A350A may suggest a possible influence on 
RCT and HDL‐C synthesis and a plausible involvement of A233S in drug metabolism [6]. The 
remaining cSNPs (I883M, cL96R and ‐62A>C), however, did not influence the  expression of 
their respective genes (ABCA1 and APOCII) despite being known to alter plasma lipid levels 
and influence cholesterol efflux [15, 16]. Therefore, these findings suggest that some of these 
identified sequence variants have significant impact on gene expression which can be corre‐
lated with biochemistry levels (HDL‐C, LDL‐C and triglycerides) following drug intervention.
Gene cSNP Accession number Chr Exon Nucleotide change Amino acid change
CETP I405V rs5882 16 14 A/G I/V
ABCA1 Ile883Met rs4149313 9 18 A/G I/M
CYP7A1 Asn233Ser rs8192874 8 3 A/G N/S
APOC‐II Leu96Arg rs5167 19 3 T/G L/R
‐62A>C rs2288911 Promoter
SR‐B1 A350A rs5888 12 8 C/T A/A
Table 1. cSNPs identified in vervet monkeys.
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5. Conclusion
It is a fact that characterisation of polymorphisms in lipid metabolism is challenging, however 
it remains essential for the optimal regulation and functioning of the RCT pathway. This review 
demonstrates that the genetic determinants of lipid transport and metabolism may provide 
additional significant benefit in pharmacological therapy for CVDs. Genetic approaches have 
shown that sequence variants can be correlated with biochemistry levels such as HDL‐C, LDL‐C 
and triglycerides following drug intervention. Although cholesterol lowering alone may explain 
the anti‐atherosclerotic effect of niacin on HDL‐C, in this review, gene expression data has shed 
some light in supporting the hypothesis that genetic variants may influence the expression of 
genes involved in RCT, which may also play a role in the anti‐atherosclerotic effect of niacin.
Figure 2. The effect of niacin treatment on HDL‐C, LDL‐C, triglycerides (Trig) and apoA‐1. *Significant level (p < 0.05).
Figure 3. The effect of niacin treatment on CETP, SR‐B1 and CYP7A1 mRNA expression. The data were expressed as 
mean ± SD and mRNA expression in a.u. (arbitrary units). *Significant level (p < 0.05).
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It is also noteworthy that this is the first report to provide data of a controlled pharmacologi‐
cal intervention linked to genetic determinants of lipid metabolism in vervet monkeys.
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